Hepatobiliary Cancer
COSMIC-312 trial
In COSMIC-312 trial, first line #Cabozantinib plus #atezolizumab improved PFS versus #sorafenib for patients with advanced HCC. In this phase...
RTOG 1112 trial
The addition of stereotactic body radiation therapy (SBRT) to sorafenib for patients with hepatocellular carcinoma (HCC) improved PFS and OS...
HIMALAYA trial
.png)
The #FDA has approved Tremelimumab plus Durvalumab for patients with unresectable #Hepatocellular Carcinoma. This approval was based on the results...
FDA approval of bevacizumab biosimilar
On September 28th 2022, the FDA has approved Celltrion’s #bevacizumab biosimilar (bevacizumab-adcd) in six types of cancers which are: metastatic...
RATIONALE-301 trial
In the non-inferiority, RATIONALE-301 study presented by Dr. Masatoshi Kudo, Single agent Tislelizumab (TIS), an anti-PD-1 monoclonal antibody, showed comparable...
Testing the combination of immunotherapy and anti-VEGFR in HCC
In a phase III study presented by Shukui Qin, the combination of #immunotherapy plus an anti-angiogenic TKI showed effectiveness as...
TOPAZ-1 trial
The FDA has approved #durvalumab (Imfinzi) in combination with gemcitabine and cisplatin in adult patients with locally advanced or metastatic...
LEAP-002 trial
In the phase III LEAP-002 study presented by Richard Finn, adding pembrolizumab to first line #Lenvatinib in HCC patients improved...
.png)